Seattle Genetics (NASDAQ:SGEN) and BIO-TECHNE (NASDAQ:TECH) Head to Head Review

Share on StockTwits

Seattle Genetics (NASDAQ:SGEN) and BIO-TECHNE (NASDAQ:TECH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Seattle Genetics and BIO-TECHNE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Seattle Genetics -37.97% -19.17% -15.99%
BIO-TECHNE 12.68% 13.36% 8.14%

Valuation and Earnings

This table compares Seattle Genetics and BIO-TECHNE’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seattle Genetics $654.70 million 30.04 -$222.69 million ($1.65) -69.55
BIO-TECHNE $714.01 million 11.34 $96.07 million $3.80 55.91

BIO-TECHNE has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Seattle Genetics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, BIO-TECHNE has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Seattle Genetics and BIO-TECHNE, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seattle Genetics 1 4 13 0 2.67
BIO-TECHNE 0 2 5 0 2.71

Seattle Genetics currently has a consensus target price of $106.00, suggesting a potential downside of 7.63%. BIO-TECHNE has a consensus target price of $206.80, suggesting a potential downside of 2.66%. Given BIO-TECHNE’s stronger consensus rating and higher probable upside, analysts plainly believe BIO-TECHNE is more favorable than Seattle Genetics.

Dividends

BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.6%. Seattle Genetics does not pay a dividend. BIO-TECHNE pays out 33.7% of its earnings in the form of a dividend.

Insider and Institutional Ownership

92.5% of Seattle Genetics shares are owned by institutional investors. Comparatively, 91.5% of BIO-TECHNE shares are owned by institutional investors. 33.8% of Seattle Genetics shares are owned by insiders. Comparatively, 4.2% of BIO-TECHNE shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BIO-TECHNE beats Seattle Genetics on 10 of the 16 factors compared between the two stocks.

Seattle Genetics Company Profile

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts’ Downgrades for December, 10th
Analysts’ Downgrades for December, 10th
CSG Systems International  Rating Lowered to Sell at ValuEngine
CSG Systems International Rating Lowered to Sell at ValuEngine
Mogo Finance Technology  Downgraded to “Hold” at ValuEngine
Mogo Finance Technology Downgraded to “Hold” at ValuEngine
ValuEngine Lowers ICU Medical  to Hold
ValuEngine Lowers ICU Medical to Hold
Beacon Securities Analysts Boost Earnings Estimates for iAnthus Capital Holdings Inc
Beacon Securities Analysts Boost Earnings Estimates for iAnthus Capital Holdings Inc
Q1 2021 EPS Estimates for Xylem Inc  Raised by Jefferies Financial Group
Q1 2021 EPS Estimates for Xylem Inc Raised by Jefferies Financial Group


© 2006-2019 Ticker Report